THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
AI Description
To collect information about treatment for severe Aortic Regurgitation (AR), which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic valve in the heart does not close tightly and allows some blood to leak back into the heart chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.
- Who can join
- adult, older adult
- Participants
- 100
- Expected completion
- 2027-09-29
- Funded by
- industry
Conditions studied
Aortic Regurgitation
What is being tested
- DEVICE: JenaValve Pericardial TAVR System
What it measures
- All-Cause Mortality at 30 days, All-Cause mortality within the first 30 days post index procedure, 30 days
Centers Participating
These centers are participating in this study. Reach out to them directly to learn more.
Baylor Scott & White The Heart Hospital – Dallas
Dallas, TX
California Pacific Medical Center (Van Ness Campus)
San Francisco, CA
Cedars-Sinai Medical Center
Los Angeles, CA
Emory University Hospital
Atlanta, GA
MedStar Washington Hospital Center
Washington, DC
Piedmont Atlanta Hospital
Atlanta, GA
University of Michigan Health System
Ann Arbor, MI
University of Washington Medical Center
Seattle, WA
Registry entry updated 2022-11-18
Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.
If you would rather we did it with you, call us on (656) 206-4686.